References
-
Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020;26(7):S147-S154.
-
Merritt JL 2nd, MacLeod E, Jurecka A, Hainline B. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord. 2020;21(4):479-493.
-
Vockley J, Burton B, Berry G, et al. Effects of triheptanoin (UX007) in patients with long-chain fatty acid disorders: results from an open label, long-term extension study. J Inherit Metab Dis. 2020;44(1):253-263.
-
Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93-106.
-
Steptoe A, Mohabir A, Mahon NG, McKenna WJ. Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart. 2000;83(6):645-650.
-
Siddiq S, Wilson BJ, Graham ID; Canadian Inherited Metabolic Diseases Research Network (CIMDRN). Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet J Rare Dis. 2016;11(1):168.
-
Baumbusch J, Mayer S, Sloan-Yip I. Alone in a crowd? Parents of children with rare diseases’ experiences of navigating the healthcare system. J Genet Couns. 2018;1:80-90.
-
Southeast Regional Genetics Network, Genetic Metabolic Dietitians International. VLCAD nutrition management guidelines. February 2019, v 1.0. 1st ed. https://southeastgenetics.org/ngp/guidelines.php/106/VLCAD%20Nutrition%20Guidelines/Version%201.0. Accessed May 12, 2021.
-
Spiekerkoetter U, Lindner M, Santer R, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009;32(4):498-505.
-
Angelini C, Federico A, Reichmann H, Lombes A, Chinnery P, Turnbull D. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol. 2006;13(9):923-929.
-
International Network for Fatty Acid Oxidation Research and Management. FAOD diagnosis. https://informnetwork.org/faod-diagnosis. Accessed May 12, 2021.
-
Van Calcar SC, Sowa M, Rohr F, et al. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach. Mol Genet Metab. 2020;131(1-2):23-37.
-
Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. The National Academies Press, 2005.
-
Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med. 2018;6(24):473.
-
Shirley M. Triheptanoin: first approval. Drugs. 2020;80(15):1595-1600.
-
Dojolvi prescribing information. Ultragenyx Pharmaceutical Inc.; 2020.
-
Ultragenyx Pharmaceutical Inc press release. Ultragenyx announces approval of Dojolvi™ (UX007/triheptanoin) in Canada for the treatment of long-chain fatty acid oxidation disorders in adults and children. February 17, 2021.
-
Vockley J, Burton B, Berry GT, et al. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis. 2019;42(1):169-177.
-
Gillingham MB, Heitner SB, Martin J, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40(6):831-843.
-
Vockley J, Longo N, Madden M, et al. Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study. Clin Nutr ESPEN. 2021;41:293-298.
-
Zand D, Doan J, Yi S, et al. Regulatory news: Dojolvi (triheptanoin) as a source of calories and fatty acids in long-chain fatty acid oxidation disorders: FDA approval summary. J Inherit Metab Dis. 2021;44(3):515-517.
-
Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med. 2021;23(5):816-829.
-
Potter BK, Chakraborty P, Kronick JB, et al; Canadian Inherited Metabolic Diseases Research Network. Achieving the “triple aim” for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genet Med. 2013;15(6):415-422.
-
McClain MR, Cooley WC, Keirns T, Smith A. A survey of the preferences of primary care physicians regarding the comanagement with specialists of children with rare or complex conditions. Clin Pediatr (Phila). 2014;53(6):566-570.